We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.58%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.2B
AUM Growth
+$58.8M
Cap. Flow
+$619M
Cap. Flow %
19.37%
Top 10 Hldgs %
58.78%
Holding
99
New
23
Increased
20
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$158M
2
ZLAB icon
Zai Lab
ZLAB
+$107M
3
ARVN icon
Arvinas
ARVN
+$93.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$70.9M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$59.4M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$81.7M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$77.3M
3
RCUS icon
Arcus Biosciences
RCUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$63.6M
5
ITOS
iTeos Therapeutics
ITOS
+$44.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
26
Voyager Therapeutics
VYGR
$181M
$27.1M 0.85%
3,557,507
– –
BCYC
27
Bicycle Therapeutics
BCYC
$274M
$24M 0.75%
+547,453
New +$25.6M
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.38B
$22.9M 0.72%
2,359,808
+1,080,633
+84% +$13.9M
EXEL icon
29
Exelixis
EXEL
$14B
$21.6M 0.67%
+951,333
New +$18.6M
JANX icon
30
Janux Therapeutics
JANX
$904M
$20.4M 0.64%
1,421,319
+9,344
+0.7% +$153K
GERN icon
31
Geron
GERN
$943M
$19.4M 0.61%
+14,285,714
New +$15.9M
OVID icon
32
Ovid Therapeutics
OVID
$427M
$19.2M 0.6%
6,117,400
+35,200
+0.6% +$111K
SWTX
33
DELISTED
SpringWorks Therapeutics
SWTX
$18.4M 0.58%
+325,881
New +$18.6M
ORIC icon
34
Oric Pharmaceuticals
ORIC
$1.23B
$18.3M 0.57%
3,418,068
-50,876
-1% -$458K
VTYX
35
DELISTED
Ventyx Biosciences
VTYX
$17.6M 0.55%
1,300,000
– –
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$8.88B
$17.3M 0.54%
790,209
+200,040
+34% +$4.05M
ARQT icon
37
Arcutis Biotherapeutics
ARQT
$3.53B
$17.2M 0.54%
+895,503
New +$15.1M
SURF
38
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$13.7M 0.43%
+4,653,000
New +$16.3M
PMVP icon
39
PMV Pharmaceuticals
PMVP
$59.2M
$13.5M 0.42%
649,786
+599,786
+1,200% +$10.6M
HOOK
40
DELISTED
HOOKIPA Pharma
HOOK
$11.4M 0.36%
+500,000
New +$8.96M
KDNY
41
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.3M 0.35%
+690,000
New +$9.38M
AKUS
42
DELISTED
Akouos Inc
AKUS
$9.39M 0.29%
1,975,984
– –
PTGX icon
43
Protagonist Therapeutics
PTGX
$8.7B
$9.04M 0.28%
381,711
-2,257,995
-86% -$63.6M
ALGS icon
44
Aligos Therapeutics
ALGS
$26.1M
$8.49M 0.27%
157,934
+154,292
+4,236% +$12.4M
NGM
45
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$8.25M 0.26%
+541,108
New +$8.44M
IGMS
46
DELISTED
IGM Biosciences
IGMS
$7.98M 0.25%
+298,597
New +$5.56M
ERAS icon
47
Erasca
ERAS
$6.27B
$5.83M 0.18%
678,441
-21,559
-3% -$250K
TNGX icon
48
Tango Therapeutics
TNGX
$4.3B
$5.78M 0.18%
761,971
-538,029
-41% -$4.66M
FLAC
49
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$5.78M 0.18%
587,615
– –
ZNTL icon
50
Zentalis Pharmaceuticals
ZNTL
$322M
$5.32M 0.17%
+115,236
New +$6.22M
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2022 Portfolio in Review

As of Q1 2022, EcoR1 Capital held 99 positions worth $3.2B, up 1.9% from $3.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $619M of net new capital in Q1 2022, opening 23 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 2,069,634 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $75.7M trimmed.

  • EcoR1 Capital's largest Q1 2022 buy was Sarepta Therapeutics: 2,069,634 shares worth $162M.
  • EcoR1 Capital added most to Arvinas in Q1 2022, an estimated $93.6M increase.
  • EcoR1 Capital's biggest Q1 2022 reduction was Arcus Biosciences, cutting an estimated $75.7M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q1 2022, selling an estimated $81.7M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $3.2B portfolio in Q1 2022.
  • EcoR1 Capital opened 23 new positions and closed 12 in Q1 2022.
  • EcoR1 Capital's portfolio value rose 1.9% quarter-over-quarter to $3.2B.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.